(1). Xiang DB, Wei B, Abraham SC, et al. Molecular cytogenetic characterization of mammary neuroendocrine carcinoma. Human Pathology, 2014, 45(9):1951-1956.
(2). WHO Classification of Tumors Editorial Board. Breast Tumours. WHO Classification of Tumors, 5th edn. Lyon, France: IARC; 2019.
(3). Menendez. Solid neuroendocrine breast carcinomas: incidence, clinico-pathological features and immunohistochemical profiling. Oncol Rep, 2008, 20(6) :1369-1374.
(4). Righi L, Sapino A, Caterina Marchiò, et al. Neuroendocrine differentiation in breast cancer: established facts and unresolved problems.[J]. Seminars in Diagnostic Pathology, 2010, 27(1):69-76.
(5). Rovera F, Lavazza M, Rosa SL, et al. Neuroendocrine breast cancer: retrospective analysis of 96 patients and review of literature. International Journal of Surgery, 2013, 11:S79-S83.
(6). Bogina G, Munari E, Brunelli M, et al. Neuroendocrine differentiation in breast carcinoma: clinicopathological features and outcome. Histopathology, 2016, 68(3):422-432.
(7). Roininen N, Takala S, Haapasaari KM, et al. Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study. BMC Cancer, 2017, 17(1): 72.
(8). Zhang Y, Chen Z, Bao Y, Du Z, Li Q, Zhao Y, et al. Invasive neuroendocrine carcinoma of the breast: a prognostic research of 107 chinese patients. Neoplasma, 2013, 60(02), 215-222.
(9). Wei B, Ding T, Xing Y, Wei Wei MS, Tian Z, Tang, F, et al. Invasive neuroendocrine carcinoma of the breast. Cancer, 2010, 116(19), 4463-4473.
(10). Wang J, Wei B, Albarracin CT, Hu J, Abraham SC, Wu Y. Invasive neuroendocrine carcinoma of the breast: a population-based study from the surveillance, epidemiology and end results (SEER) database. BMC Cancer, 2014, 14:147.
(11). Kwon SY, Bae YK, Gu MJ, et al. Neuroendocrine differentiation correlates with hormone receptor expression and decreased survival in patients with invasive breast carcinoma. Histopathology, 2014, 64(5):647-659.
(12). Tian Z, Wei B, Tang F, et al. Prognostic significance of tumor grading and staging in mammary carcinomas with neuroendocrine differentiation. Hum Pathol, 2011, 42(8):1169-1177.
(13). Pareja F, D'Alfonso TM. Neuroendocrine neoplasms of the breast: A review focused on the updated World Health Organization (WHO) 5th Edition morphologic classification. Breast J, 2020, 26(6):1160-1116.
(14). Safini F, Bouchbika Z, Bennani Z, et al. Primary large cell neuroendocrine carcinoma of the breast: a rare tumor in humans. Pan Afr Med J, 2016, 25():205.
(15). Yoshimura N, Sasada T, Yonehara S. Primary Large-Cell Neuroendocrine Carcinoma of the Breast Occurring in a Pre-Menopausal Woman. Breast Care (Basel), 2015, 10(4):281-283.
(16). Janosky M, Bian J, Dhage S, et al. Primary large cell neuroendocrine carcinoma of the breast, a case report with an unusual clinical course. Breast J, 2015, 21(3):303-307.
(17). Omachi N, Shimizu S, Kawaguchi T, et al. A case of large-cell neuroendocrine carcinoma harboring an EML4-ALK rearrangement with resistance to the ALK inhibitor crizotinib. J Thorac Oncol, 2014, 9(6):e40-42.
(18). Psoma E, Nikolaidou O, Stavrogianni T, et al. A rare case report of a primary large-cell neuroendocrine carcinoma of the breast with coexisting Paget disease. Clin Imaging, 2012, 36(5):599-601.
(19). Okoshi K, Saiga T, Hisamori S, et al. A case of cytokeratin 20-positive large-cell neuroendocrine carcinoma of the breast. Breast Cancer, 2012, 19(4):360-364.
(20). Kim JW, Woo OH, Cho KR, et al. Primary large cell neuroendocrine carcinoma of the breast: radiologic and pathologic findings. J Korean Med Sci, 2008, 23(6):1118-1120.
(21). Park YM, Wu Y, Wei W, Yang WT. Primary neuroendocrine carcinoma of the breast: Clinical, imaging, and histologic features. AJR Am. J. Roentgenol, 2014, 203(): W221–W230.
(22). Cloyd JM, Yang RL, Allison KH, et al. Impact of histological subtype on long-term outcomes of neuroendocrine carcinoma of the breast. Breast Cancer Res Treat, 2014, 148():637-644.
(23). Roininen N, Takala S, Haapasaari KM, et al. Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study. BMC Cancer, 2017, 17:72.
(24). Kelten Talu C, Leblebici C, Kilicaslan Ozturk T, et al. Primary breast carcinomas with neuroendocrine features: clinicopathological features and analysis of tumor growth patterns in 36 cases. Ann Diagn Pathol, 2018, 34:122-130.
(25). Lavigne M, Menet E, Tille JC, et al. Comprehensive clinical and molecular analyses of neuroendocrine carcinomas of the breast. Mod Pathol, 2018, 31:68-82.
(26). Abdelwahed A, Ahmed M. Rare epithelial breast cancer: Surgery and adjuvant therapy. Transl. Cancer Res, 2019, 8: S479–S492.
(27). Kawasaki T, Mochizuki K, Yamauchi H, et al. High prevalence of neuroendocrine carcinoma in breast lesions detected by the clinical symptom of bloody nipple discharge. Breast, 2012, 21(5):652-656.
(28). Richter-Ehrenstein C, Arndt J, Buckendahl AC, Eucker J, Weichert W, Kasajima A, Schneider A, Noske A. Solid neuroendocrine carcinomas of the breast: Metastases or primary tumors? Breast Cancer Res. Treat, 2010, 124, 413–417.